NCT04110496View on ClinicalTrials.gov

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 29, 2020

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Phenylketonurias
Interventions
DRUG

RTX-134

RTX-134 is a cellular therapy containing AvPAL

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

Sponsors
All Listed Sponsors
lead

Rubius Therapeutics

INDUSTRY